Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

Duration of protection from SARS-CoV-2 infection in people with HIV (PWH) following vaccination is unclear. In a sub-study of the phase 2/3 the COV002 trial (NCT04400838), 54 HIV positive male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells >350 cells/ul) received two doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and MesoScale Discovery (MSD)), neutralisation, ACE-2 inhibition, gamma interferon ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that 6 months after vaccination the majority of measurable immune responses were greater than pre-vaccination baseline, but with evidence of a decline in both humoral and cell mediated immunity. There was, however, no significant difference compared to a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although were lower than wild type. Pre-existing cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater post-vaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the on-going policy to vaccinate PWH against SARS-CoV-2, and underpin the need for long-term monitoring of responses after vaccination.

[1]  P. Klenerman,et al.  Divergent trajectories of antiviral memory after SARS-CoV-2 infection , 2021, Nature Communications.

[2]  S. Madhi,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial , 2021, The Lancet HIV.

[3]  J. Mascola,et al.  Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.

[4]  M. Lipsitch,et al.  Covid-19 Breakthrough Infections in Vaccinated Health Care Workers , 2021, The New England journal of medicine.

[5]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[6]  A. Sette,et al.  Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory , 2021, medRxiv.

[7]  F. Balloux,et al.  Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 infection , 2021, medRxiv.

[8]  P. Klenerman,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial , 2021, The Lancet HIV.

[9]  W. Haining,et al.  Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy , 2021, Frontiers in Immunology.

[10]  M. Koopmans,et al.  SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients , 2021, Science Immunology.

[11]  J. Mascola,et al.  Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants , 2021, bioRxiv.

[12]  P. Klenerman,et al.  Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses , 2021, medRxiv.

[13]  P. Klenerman,et al.  Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection , 2021, SSRN Electronic Journal.

[14]  K. Schnatbaum,et al.  Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination , 2021, Science.

[15]  L. Anderson,et al.  The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein , 2021, Virology.

[16]  D. Ho,et al.  Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.

[17]  P. Dormitzer,et al.  Neutralizing Activity of BNT162b2-Elicited Serum , 2021, The New England journal of medicine.

[18]  J. Ochoa,et al.  Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma , 2021, PloS one.

[19]  B. Haynes,et al.  Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors , 2021, Cell reports. Medicine.

[20]  D. Stuart,et al.  Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera , 2021, Cell.

[21]  S. Rowland-Jones,et al.  Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV , 2021, Nature Communications.

[22]  N. Jones,et al.  Risk of adverse coronavirus disease 2019 outcomes for people living with HIV , 2021, AIDS (London, England).

[23]  David R. Holtgrave,et al.  COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State , 2021, JAMA network open.

[24]  D. Rader,et al.  Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection , 2021, Cell.

[25]  D. Ho,et al.  Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 , 2021, bioRxiv.

[26]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[27]  M. Davenport,et al.  Decay of Fc-dependent antibody functions after mild to moderate COVID-19 , 2020, Cell Reports Medicine.

[28]  Nguyen H. Tran,et al.  Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. , 2020, Lancet.

[29]  P. Klenerman,et al.  T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses , 2020, Nature Communications.

[30]  C. Butler,et al.  Risk of adverse COVID-19 outcomes for people living with HIV: a rapid review and meta-analysis. , 2020, AIDS.

[31]  J. Mascola,et al.  Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination , 2020, The New England journal of medicine.

[32]  Nguyen H. Tran,et al.  T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial , 2020, Nature Medicine.

[33]  L. Carter,et al.  Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19 , 2020, Cell.

[34]  D. Rader,et al.  Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection , 2020, medRxiv.

[35]  C. Cordon-Cardo,et al.  Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.

[36]  C. Sabin,et al.  Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  P. Bieniasz,et al.  Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with recent seasonal coronavirus infection , 2020, medRxiv : the preprint server for health sciences.

[38]  N. Hacohen,et al.  Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity , 2020, Science.

[39]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[40]  S. Mallal,et al.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.

[41]  U. Reimer,et al.  SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.

[42]  Nguyen H. Tran,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.

[43]  Martin Linster,et al.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.

[44]  O. Tsang,et al.  Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses , 2020, Immunity.

[45]  Christopher Earl,et al.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.

[46]  Graham W. Taylor,et al.  Responses to Quadrivalent Influenza Vaccine Reveal Distinct Circulating CD4+CXCR5+ T Cell Subsets in Men Living with HIV , 2019, Scientific Reports.

[47]  F. Zanini,et al.  Influenza Vaccination Can Broadly Activate the HIV Reservoir During Antiretroviral Therapy , 2018, Journal of acquired immune deficiency syndromes.

[48]  A. Hill,et al.  CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria , 2018, Front. Immunol..

[49]  N. Funderburg,et al.  Inflammation, Immune Activation, and Antiretroviral Therapy in HIV , 2017, Current HIV/AIDS Reports.

[50]  S. Madhi,et al.  Risk factors associated with hospitalisation for influenza-associated severe acute respiratory illness in South Africa: A case-population study. , 2016, Vaccine.

[51]  Felipe García,et al.  Standard vaccines increase HIV-1 transcription during antiretroviral therapy , 2016, AIDS.

[52]  H. Ueno,et al.  ICOS+PD-1+CXCR3+ T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination , 2016, Scientific Reports.

[53]  J. Brooks,et al.  Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  E. Janoff,et al.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. , 2009, The Lancet. Infectious diseases.

[55]  Jennifer M. Taylor,et al.  Effects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice. , 2008, Microbial pathogenesis.

[56]  E. Tanzi,et al.  Safety and immunogenicity of influenza vaccination in individuals infected with HIV. , 2002, Vaccine.

[57]  Malbea A Lapete,et al.  Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices ( ACIP ) , 2004 .

[58]  N. Cox,et al.  Prevention and control of influenza , 1999, The Lancet.

[59]  D. Scott,et al.  Vaccine Strategies: Targeting Helper T Cell Responses , 1995, Annals of the New York Academy of Sciences.

[60]  J. D. de Jong,et al.  Antibody response to influenza, tetanus and pneumococcal vaccines in HIV‐seropositive individuals in relation to the number of CD4+ lymphocytes , 1994, AIDS.